SARS-CoV-2 neutralizing antibody development strategies | Zendy

Bertan Koray Balcıoğlu | Zendy; Melis DENİZCİ ÖNCÜ | Zendy; Hasan Ümit Öztürk | Zendy; Fatıma Yücel | Zendy; Filiz Kaya | Zendy; Müge Serhatlı | Zendy; Hivda Ülbeği Polat | Zendy; Şaban Teki̇n | Zendy; Aylin Özdemir Bahadır | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

SARS-CoV-2 neutralizing antibody development strategies

Author(s) -

Bertan Koray Balcıoğlu,

Melis DENİZCİ ÖNCÜ,

Hasan Ümit Öztürk,

Fatıma Yücel,

Filiz Kaya,

Müge Serhatlı,

Hivda Ülbeği Polat,

Şaban Teki̇n,

Aylin Özdemir Bahadır

Publication year - 2020

Publication title -

turkish journal of biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.323

H-Index - 38

eISSN - 1303-6092

pISSN - 1300-0152

DOI - 10.3906/biy-2005-91

Subject(s) - virology , antibody , pandemic , neutralizing antibody , biology , covid-19 , virus , coronavirus , neutralization , transmission (telecommunications) , disease , immunology , infectious disease (medical specialty) , medicine , electrical engineering , engineering

In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targeted-therapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARS-CoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research